The aim of this study is to investigate the long-term immunogenicity and safety of the inactivated split-virion vaccine after one immunization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
480
120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
Hunan Provincial Center of Disease Prevention and Control
Changsha, Hunan, China
Hemagglutination inhibition antibody titer
Time frame: Day 180
occurrence of solicited local and systemic adverse events after vaccination
Time frame: Days 0-42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
120 adults were assigned to receive 1 dose of placebo.